Compare IQV & AU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IQV | AU |
|---|---|---|
| Founded | 1982 | 1944 |
| Country | United States | United States |
| Employees | 93000 | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.1B | 48.0B |
| IPO Year | 2013 | 2023 |
| Metric | IQV | AU |
|---|---|---|
| Price | $278.80 | $83.60 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 22 | 8 |
| Target Price | ★ $299.11 | $116.38 |
| AVG Volume (30 Days) | 1.1M | ★ 1.8M |
| Earning Date | 10-27-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 4.18% |
| EPS Growth | ★ 4.67 | N/A |
| EPS | ★ 1.61 | N/A |
| Revenue | ★ $9,739,000,000.00 | N/A |
| Revenue This Year | $6.78 | $25.61 |
| Revenue Next Year | $6.06 | $7.59 |
| P/E Ratio | $171.99 | ★ $23.93 |
| Revenue Growth | ★ 41.60 | N/A |
| 52 Week Low | $154.50 | $62.55 |
| 52 Week High | $282.98 | $129.14 |
| Indicator | IQV | AU |
|---|---|---|
| Relative Strength Index (RSI) | 64.85 | 31.40 |
| Support Level | $252.55 | $75.66 |
| Resistance Level | N/A | $83.93 |
| Average True Range (ATR) | 8.06 | 2.62 |
| MACD | 1.35 | -0.48 |
| Stochastic Oscillator | 85.22 | 11.69 |
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
Anglogold Ashanti PLC is an independent gold mining company. It has a diversified asset portfolio, including production from operations in eight countries (Argentina, Australia, Brazil, Egypt, Ghana, Guinea, the DRC, and Tanzania), supported by greenfield projects in the United States and Colombia. The company's main product is gold, which once mined, is processed into dore (unrefined gold bars) on site and then dispatched to precious metals refineries. Geographically, Anglogold generates maximum revenue from its operations in Africa (comprising operations at Kibali, Iduapriem, Obuasi, Siguiri, Geita, and Sukari mines), followed by Australia (including Sunrise Dam and Tropicana), and the Americas (comprising Cerro Vanguardia, AngloGold Ashanti Mineracao, and Serra Grande operations).